 Name: ___       Unit No:  ___  Admission Date: ___       Discharge Date:  ___  Date of Birth: ___       Sex:  F  Service: MEDICINE  Allergies: Penicillins / Sulfa (Sulfonamide Antibiotics) / dapsone  Attending: ___  ___ Complaint: worsening back pain  Major Surgical or Invasive Procedure: none

 History of Present Illness: Ms. ___ is a ___ y/o female dx with IgA lambda Multiple myeloma originally dx in ___. She is s/p multiple treatments in the past most recently s/p cycle 1 of velcade/dex administered weekly as of ___. She was admitted from clinic due to worsening back pain. She has a history of spinal stenosis involving L4-L5, T12 compression fx, and osteopenia. She does not have a history of lytic lesions. She presents with worsening back pain over the last weekend and concern for myeloma reoccurance.

 Past Medical History: * Status post 2-CdA therapy with Cytoxan and Rituxan in ___ and ___. * Status post six cycles of Velcade completing on ___. * Brief trial of thalidomide starting at the end of ___ and increasing doses to 100 mg with poor tolerance due to complaints of lightheadedness and fatigue. Thalidomide discontinued in ___, restarted thalidomide on ___ and continued this until ___ at a lower dose. * Enrolment on the dendritic cell/tumor vaccine study ___ with successful generation of vaccine. Received a total of four vaccines with her last vaccine on ___ with evidence of disease progression approximately five months after her vaccine therapy. * Started pulse Decadron therapy at 20 mg daily for six days on ___. * Restarted Decadron at 20 mg daily for two days per week for three-week cycle, then in ___ began on two days of Decadron every other week, which was discontinued at the end of ___ with an excellent response to therapy. * Noted for increase in IgA and completed two pulses of Decadron 20 mg daily for two days taken weekly for three weeks with first pulse on ___ and second pulse on ___. * Another pulse of Decadron 20 mg daily for two days for three weeks, started on ___. * Pulse of Decadron 20 mg daily for 2 days/week for 3 weeks starting ___. * Trial of Curcumin, 1000 mg twice per day(2 tablets twice per day). Stopped in ___ due to side effects. * Decadron pulse starting on ___: 2 days of 20 mg, followed by 2 days of 4 mg; repeated the following week. * Decadron pulse in mid ___ with 20 mg daily for 3 days prior to aortic valve replacement on ___. * Decadron pulse in mid ___ with 10 mg for 2 days followed by 2 days of 4 mg and repeated in 1 week.  * Decadron pulse in late ___ with 12 mg for 4 days, hold for 5 days and then repeat Decadron 12 mg for 4 days. * Increasing shortness of breath with repeat echocardiogram and evaluation by cardiologist. No issues regarding her aortic valve. Diltiazem dose decreased as her blood pressure was lower. 

Received unit of red cells on ___ for Hct ~ 30%with no significant change in her symptoms. CT scan of the chest showed some small nodules but felt not enough to contribute to her dyspnea. Etiology felt related to deconditioning with decreased activity. * Increasing lower back pain radiating down her left leg. Has severe spinal stenosis; underwent steroid epidural injection at L3-4 on ___ with marked improvement in her pain. * Slowly increasing IgA level and took another Decadron pulse in ___ of 20 mg daily for 3 days, then 8 mg for 2 days, then 4 mg for 2 days.  * Slowly increasing IgA level and took another Decadron pulse in ___ of 20 mg daily for 4 days, then 8 mg for 2 days, then 4 mg for 2 days.  * Increasing IgA once again and received Decadron pulse of 20 mg for 2 days, followed by 8 mg for 2 days and 4 mg for 2 days, then 1 cycle of Velcade 1 mg/m2 SQ and Decadron on day of Velcade for 3 weeks in ___. * IgA slightly increased but more noted increasing BJP excretion of 3200 mg/day as of ___. Given Decadron pulse 20 mg 2 days, then 8 mg for 2 days, then 4 mg for 2 days as of ___ and then on ___, initiated another cycle of Velcade ~ 1 mg/m2 on D 1, 8, 15 with Decadron on day of treatment. * ___, noted for increasing creatinine to 2.3 with increased free light chain ratio and increased BJP excretion. Started on Velcade @ 1 mg/m2 and Decadron with 3 weeks on, 1 week of with additional short pulse of Decadron 12 mg for 4 days starting on D 1. * ___, Velcade @ 1 mg/m2 with Decadron 10 mg weekly x 3 weeks. * ___, presents for next cycle. * ___, Velcade @ 1.3 mg/m2 with Decadron 10 mg weekly x 3 weeks.  * ___, 10 g IVIG * Persistent cough and admitted on ___ with cough with hypoxia. Noncontrast chest CT was negative for pulmonary infiltrate or sign of fluid overload. Lung scan was consistent with low probability of pulmonary embolism. Discharged with home oxygen which she uses as needed with improvement over time. * Increasing IgA and FLC assay. Treatment schedule switched to Velcade D 1,4,8 and 11 with Decadron on day of and day after Velcade. D1 given on ___. D 8 held due to noted hemolysis felt related to Decadron. * ___ Velcade D 1,4,8 and 11 with Decadron on day of and day after Velcade. D 11 held with increased dyspnea. * ___ Admitted with unstable angina, CHF and cardionyopathy. Medications adjusted. * ___ switched to velcade/dex day 1 and 4 every other week

PAST MEDICAL/SURGICAL HISTORY (per NP ___ ___ note, confirmed with patient):  1. Severe abdominal pain in ___ requiring admission; CT scan showed ischemic colitis of transverse colon at splenic flexure. Treated with bowel rest and antibiotics. Discharged on ___ with improved symptoms. Repeat colonoscopy on ___ showed ischemic colitis. 2. CAD status post CABG x 2 in ___ and ___.  3. Critical aortic stenosis with aortic valve replacement on ___. Experimental surgical technique used approach through the left lateral chest wall. 4. Multiple myeloma as above. 5. Hypertension; Hyperlipidemia 6. Zoster 7. Paroxysmal atrial fibrillation 8. Hypothyroidism  Social History: ___ Family History: Her father died of MI. Mother died of EtOH cirrhosis. No known h/o clots.  Physical Exam: PHYSICAL EXAM: GEN: WDWN NAD A&Ox4 HEENT: oropharynx moist. CV: irreg irreg no m/r/g PULM: CTA ABD: soft protuberant +BS NT EXTR: No edema, no inguinal adenopathy SKIN: No rashes or skin breakdown NEURO: Grossly nonfocal, alert and oriented No paraspinous tenderness

 Pertinent Results: ___ 01:05PM  ___ ___ ___ 01:05PM  PLT COUNT-212 ___ 01:05PM  NEUTS-81.7* LYMPHS-11.8* MONOS-5.9 EOS-0.6 BASOS-0.2 ___ 01:05PM  WBC-14.4* RBC-3.78* HGB-11.7* HCT-35.7* MCV-94 MCH-30.8 MCHC-32.7 RDW-15.7* ___ 01:05PM URINE U-PEP-ABNORMAL B ___ 01:05PM URINE HOURS-RANDOM CREAT-68 TOT PROT-99 PROT/CREA-1.5* ___ 01:05PM  Free K-12.5 Free L-201.1* Fr K/L-0.06* IgG-343* IgA-31* IgM-27* ___ 01:05PM  TSH-5.2* ___ 01:05PM  TOT PROT-5.9* ALBUMIN-4.3 GLOBULIN-1.6* CALCIUM-10.0 MAGNESIUM-2.0 ___ 01:05PM  ALT(SGPT)-23 AST(SGOT)-28 LD(LDH)-313* ALK PHOS-76 TOT BILI-0.5 ___ 01:05PM  UREA N-24* CREAT-1.0 SODIUM-140 POTASSIUM-5.1 CHLORIDE-100 TOTAL CO2-29 ANION GAP-___ year old female with IgA lambda mulitple myeloma most recently s/p C1 of vel/dex weekly. She was admitted from clinic on ___ secondary to acute on chronic back pain.

# Multiple Myeloma: The patient initiated vel/dex weekly as palliation treatment as of ___. She was due to initiate cycle 2 on ___ consisting of SQ velcade and dexamethasone the day on and after velcade. This is currently held until post kypoplasty procedure. She will follow up with hematology on ___ for further discussion of treatment.

#Compression fx and spinal stenosis. The patient has a history of chronic back pain secondary to spinal stenosis, compression fx s/p kyphoplasty, and osteopenia. The patient does not have a history of lytic lesions associated with her myeloma. Patient MRI of thoracic/lumbar spine ___ consistnet with new T10 compression fx. To undergo kypoplasty with Dr. ___ spine physician, as an outpatient. F/u with Dr ___ has been arranged for ___. On vit D.

# Pain control. Secondary to chronic back pain as stated above. Will continue tylenol prn. Pain medications at home include dilaudid prn, vicodin prn, and gabapentin. She does not like narcotics or her gabapentin as it makes her drowsy. She has not been taking gabapentin or vicodin. She has been seen by Dr. ___ in regards to pain management and spine. She last received a steriod injection ___ which alleviated her lumbar radiculopathy. She will continue lidoderm patch for relief. Pain service continues to follow up. She will use the dilaudid po at home. The 4mg dose seems to help prior to activity. This has been discussed with the patient. She will remain on her home bowel regimen of colace, senna, and prunes.

# esophageal dilation: seen incidentally on MRI. was present at least since ___ per radiology. minimal sx, of a recent duration. would defer this workup, if needed, until after acute issues have been dealt with.

#Cardio. Patient has an extensive cardiac history including CAD s/p 2 bypass surgeries, aortic stenosis, s/p valve replacement, CHF, and paroxysmal a fib. She is seen regularly by her cardiologist Dr. ___ follow ups. 1 unit of pRBC's was given on ___ for her known coronary disease in the setting of anemia.

# Renal insufficiency. Secondary to multiple myeloma. Remained stable. Cr baseline 1.0-1.4. 

# Infectious prophylaxis: - PCP: pentamidine monthly, received in-house on ___ prior to discharge. - HSV/VZV: acyclovir

Prophylaxes: # Access: peripheral # FEN: Regular diet # Bowel regimen: colace, senna prn # Contact: ___ # Disposition: home today with sister. ___ evaluated, no recomendation for services. # Code status: full

 Medications on Admission: The Preadmission Medication list is accurate and complete. 1. Acyclovir 400 mg PO Q12H 2. ALPRAZolam 0.5-1 mg PO ONCE pre MRI 3. Atorvastatin 80 mg PO DAILY 4. ClonazePAM 0.5-1 mg PO QHS:PRN insomnia 5. Digoxin 0.125 mg PO QMOWEFR 6. Diltiazem Extended-Release 120 mg PO Q12H 7. Furosemide 20 mg PO DAILY 8. HYDROmorphone (Dilaudid) 2 mg PO Q4H:PRN pain 9. Levothyroxine Sodium 100 mcg PO DAILY 10. Hydrocodone-Acetaminophen (5mg-500mg) ___ TAB PO Q6H:PRN pain 11. Metoprolol Tartrate 25 mg PO BID 12. Pentamidine-Inhalation 300 mg IH ONCE 13. Lidocaine 5% Patch 1 PTCH TD QAM 14. Aspirin 325 mg PO DAILY 15. Nephrocaps 1 CAP PO DAILY 16. Vitamin D 1000 UNIT PO DAILY 17. Cyanocobalamin 500 mcg PO DAILY 18. Docusate Sodium 100 mg PO BID:PRN constipation 19. Fish Oil (Omega 3) 1000 mg PO DAILY 20. Pyridoxine 50 mg PO DAILY 21. Senna 1 TAB PO BID:PRN constipation 

 Discharge Medications: 1. Acyclovir 400 mg PO Q12H 2. Aspirin 325 mg PO DAILY 3. Atorvastatin 80 mg PO DAILY 4. ClonazePAM 0.5-1 mg PO QHS:PRN insomnia 5. Cyanocobalamin 500 mcg PO DAILY 6. Digoxin 0.125 mg PO QMOWEFR 7. Diltiazem Extended-Release 120 mg PO Q12H 8. Docusate Sodium 100 mg PO BID:PRN constipation 9. Fish Oil (Omega 3) 1000 mg PO DAILY 10. Furosemide 20 mg PO DAILY 11. Levothyroxine Sodium 100 mcg PO DAILY 12. Lidocaine 5% Patch 1 PTCH TD QAM 13. Metoprolol Tartrate 25 mg PO BID 14. Nephrocaps 1 CAP PO DAILY 15. Pentamidine-Inhalation 300 mg IH ONCE Duration: 1 Dose FOR INHALATION ONLY *Admin/Prep Precautions* 16. Pyridoxine 50 mg PO DAILY 17. Senna 1 TAB PO BID:PRN constipation 18. Vitamin D 1000 UNIT PO DAILY 19. Acetaminophen 325-650 mg PO Q6H:PRN pain 20. HYDROmorphone (Dilaudid) ___ mg PO Q4H:PRN pain RX *hydromorphone 2 mg ___ tablet(s) by mouth every four (4) hours Disp #*90 Tablet Refills:*0

 Discharge Disposition: Home  Discharge Diagnosis: primary t10 compression fracture myeloma anemia urinary tract infection

 Discharge Condition: Mental Status: Clear and coherent. Level of Consciousness: Alert and interactive. Activity Status: Ambulatory - Independent.

 Discharge Instructions: You were admitted to the hospital to help control a sudden worsening of your chronic back pain and to make sure you did not 

have a compression of your spinal cord. You had an MRI which showed no spinal cord compression but did show a possible new vertebral compression fracture at T10. Your pain was controlled initially with IV Dilaudid which was then switched to a Dilaudid pill. If your pain is well controlled, you do not need any further intervention for your vertebral compression fracture at this time.

 Followup Instructions: ___ 